41.70
+0.29%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biocytogen Pharmaceuticals (Beijing) Co
Its shares trade on HKEX under the ticker 2315.HK. It has been listed since 1 September 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.61bn and net income of CN¥201.7m. At that date it held total assets of CN¥4.34bn and shareholders' equity of CN¥2.53bn.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Sept 2022
- Employees
- 1,313
- Website
- biocytogen.com.cn ↗
Leadership
Pay as last reported
- Dr. Yuelei ShenExecutive Chairman of the Board, Chief Executive Officer, General Manager, since 2009CN¥5.8m
- Mr. Bin LiuChief Financial Officer
- Dr. Yi YangChief Scientific Officer, Deputy General Manager
- Mr. Yongliang WangDeputy General Manager, Joint Company Secretaries, Chief Secretariat Officer
- Dr. Zhaorong ChenDeputy General Manager, Chief Medical Officer of Eucure (Beijing)
- Dr. Chaoshe GuoDeputy General Manager
- Dr. Zhihong LiDeputy General Manager, Chief Regulatory and Strategy Officer of Eucure (Beijing)
- Dr. Qingcong LinDeputy General Manager
- Ms. You WangDeputy General Manager, Chief Operation Officer of Eucure (Beijing)
- Dr. Zhaoxue YuDeputy General Manager
- Ms. Yan ZhuDeputy General Manager
- Dr. Haichao ZhangExecutive Director, Senior Operation Director of Animal Center, since 2019CN¥1.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biocytogen Pharmaceuticals employs 1313 full-time staff members in Beijing.
- The Drug Development segment focuses on oncology treatment research.
- The Preclinical Research segment engages in gene editing services.
Weaknesses
- The company operates only two distinct business segments.
- Biocytogen Pharmaceuticals is headquartered in Beijing, China.
- The firm went public on 1 September 2022.
Opportunities
- The Drug Development segment researches autoimmune disease treatments.
- The Preclinical Research segment sells model animals for studies.
- The company provides related biological services to clients.
Threats
- The company manufactures biological products in Beijing.
- Biocytogen Pharmaceuticals operates in the Biotechnology industry.
- The firm is listed on the Chinese stock market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.